ArticleBlood advances2021
Systemic bevacizumab for refractory bleeding and transfusion-dependent anemia in Heyde syndrome.
Article in Blood advances, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.
- Effectiveness of aortic valve replacement in Heyde syndrome: a meta-analysis.European heart journal · 2023Pooled it
- Systemic Bevacizumab for Severe Bleeding From Acquired Gastrointestinal Vascular Malformations.American journal of hematology · 2026Observational
- Sirolimus and gastrointestinal angiodysplasia: Can an established agent change the way gastrointestinal bleeding is managed?World journal of gastroenterology · 2025Article
- Management challenges in Heyde syndrome: A case report of recurrent gastrointestinal bleeding and aortic stenosis in an octogenarian.Global cardiology science & practice · 2025Article
- Heyde Syndrome Unveiled: A Case Report with Current Literature Review and Molecular Insights.International journal of molecular sciences · 2024Review
- Gastrointestinal Angiodysplasia Resolution After Transcatheter Aortic Valve Implantation.JAMA network open · 2024Article
- Recent advances in the treatment of refractory gastrointestinal angiodysplasia.United European gastroenterology journal · 2024Review
- Transcatheter aortic valve implantation for patients with heyde syndrome: A literature review of case reports.Heliyon · 2023Review
- Tranexamic acid may be a useful pharmacotherapy for endoscopically resistant small bowel angiodysplasia.World journal of gastroenterology · 2023Review
- Article
- Systemic bevacizumab as salvage therapy for persistent severe bleeding and anemia in heyde syndrome following aortic valve replacement.Journal of thrombosis and thrombolysis · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heyde syndrome, the co-occurrence of aortic stenosis and bleeding gastrointestinal (GI) angiodysplasia, is managed with aortic valve replacement. However, severe bleeding and anemia can preclude safe use of the antiplatelet or anticoagulant therapy required for this intervention. We present a case of the novel and successful treatment of severe, refractory bleeding and transfusion dependence with antiangiogenic therapy in a patient with Heyde syndrome. After systemic bevacizumab was initiated, the patient achieved durable hemostasis with normalization of hemoglobin and liberation from red cell transfusion and dependence on iron infusion; aspirin therapy was successfully initiated where it had previously failed. This durable hemostasis facilitated her subsequent successful transcatheter aortic valve replacement. Plasma vascular endothelial growth factor levels, which were monitored during therapy, paradoxically rose after bevacizumab was initiated but normalized after it was discontinued. Given the angiogenic dysregulation of Heyde syndrome, systemic bevacizumab may be an effective and safe targeted therapy for managing refractory GI bleeding, which thereby facilitates antiplatelet therapy and aortic valve replacement in these challenging cases. Additional investigation into the therapeutic role of inhibiting angiogenesis as a hemostatic modality in Heyde syndrome is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.